{"id":"NCT02457819","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Dasotraline Pediatric Extension Study","officialTitle":"An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-30","primaryCompletion":"2017-02-02","completion":"2017-02-02","firstPosted":"2015-05-29","resultsPosted":"2020-01-18","lastUpdate":"2020-01-28"},"enrollment":237,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Dasotraline","otherNames":[]}],"arms":[{"label":"Dasotraline","type":"EXPERIMENTAL"}],"summary":"This is an open label 26 week extension study for subjects who completed SEP360-202.","primaryOutcome":{"measure":"The Incidence of Overall Adverse Events, AEs , Serious Adverse Envents,(or SAEs), and AEs (or SAEs) Leading to Discontinuation","timeFrame":"26 Weeks","effectByArm":[{"arm":"Dasotraline","deltaMin":144,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":6},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":236},"commonTop":["Decreased apppetite","Weight decreased","Headache","Initial insomnia","Irritability"]}}